Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 167.50
-15.50 (-8.47%)
At close: Dec 5, 2025
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 13.42M TWD in the quarter ending September 30, 2025, a decrease of -42.32%. This brings the company's revenue in the last twelve months to 34.99M, down -29.99% year-over-year. In the year 2024, Caliway Biopharmaceuticals had annual revenue of 44.43M with 14.13% growth.
Revenue (ttm)
34.99M
Revenue Growth
-29.99%
P/S Ratio
7,424.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
259.78B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 13.82B |
| Lotus Pharmaceutical | 18.66B |
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |
| Center Laboratories | 1.57B |
| Pegavision | 6.90B |
| Polaris Group | 70.83M |